These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37545470)

  • 1. Short-term outcomes after sodium-glucose cotransporter-2 inhibitor initiation in a cohort of heart failure patients.
    Pérez Martínez BO; Adie SK; Marshall VD; Konerman MC
    ESC Heart Fail; 2023 Oct; 10(5):3223-3226. PubMed ID: 37545470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure.
    Nakagaito M; Imamura T; Ushijima R; Nakamura M; Kinugawa K
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.
    Pierce JB; Vaduganathan M; Fonarow GC; Ikeaba U; Chiswell K; Butler J; DeVore AD; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Linganathan KK; McDermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Greene SJ
    JAMA Cardiol; 2023 Jul; 8(7):652-661. PubMed ID: 37212192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
    Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Loop Diuretic Dosing Following Sodium-Glucose Cotransporter 2 Inhibitor Initiation in Patients With Heart Failure.
    Trudeau BM; Allen LA; Billups SJ; Saseen JJ; Pearson SM
    J Pharm Pract; 2023 Dec; 36(6):1330-1335. PubMed ID: 35848505
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of Inpatient Initiation of Sodium-Glucose Cotransporter-2 Inhibitors on Prescription Rates in Patients With Heart Failure With Reduced Ejection Fraction.
    Okoroike H; Patel S; Simone P; Lavelle R; Szwak JA
    Am J Cardiol; 2023 Jan; 186():150-155. PubMed ID: 36283884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
    Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
    ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population.
    Li W; Katamreddy A; Kataria R; Myerson ML; Taub CC
    Drugs Real World Outcomes; 2022 Mar; 9(1):53-62. PubMed ID: 34478119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
    Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
    Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis.
    Yan Y; Liu B; Du J; Wang J; Jing X; Liu Y; Deng S; Du J; She Q
    ESC Heart Fail; 2021 Jun; 8(3):2210-2219. PubMed ID: 33749159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial).
    Jariwala P; Jadhav K; Punjani A; Boorugu H; Mari AR
    Indian Heart J; 2021; 73(5):605-611. PubMed ID: 34627577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
    Green JB; McCullough PA
    Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study.
    Hsiao FC; Lin CP; Tung YC; Chang PC; McMurray JJV; Chu PH
    Int J Cardiol; 2021 May; 330():91-97. PubMed ID: 33587940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry).
    Jiménez-Blanco Bravo M; Valle A; Gayán Ordás J; Del Prado Díaz S; Cordero Pereda D; Morillas Climent H; Bascompte Claret R; Seller Moya J; Zamorano Gómez JL; Alonso Salinas GL
    J Cardiovasc Pharmacol; 2021 Nov; 78(5):e662-e668. PubMed ID: 34321396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor.
    Chan YH; Chao TF; Chen SW; Kao YW; Huang CY; Chu PH
    Eur Heart J Qual Care Clin Outcomes; 2023 Jun; 9(4):397-407. PubMed ID: 35797996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes.
    Varshney N; Billups SJ; Saseen JJ; Fixen CW
    Ther Adv Drug Saf; 2021; 12():2042098621997703. PubMed ID: 33854754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Inpatient Initiation of SGLT2 Inhibitors on Diuretic Requirements in Patients With Heart Failure.
    Cavagnini ME; Best EE; Skersick PT; Truitt KP; Musick KL; Mangum BR; Hollis IB; Rodgers JE
    J Pharm Pract; 2024 Jun; 37(3):683-689. PubMed ID: 37032494
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of sacubitril-valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta-analysis.
    Mo X; Lu P; Yang X
    Clin Cardiol; 2023 Oct; 46(10):1137-1145. PubMed ID: 37465885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium glucose cotransporter-2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function.
    Chan YH; Hsu TJ; Wang CL; Kao YW; Huang CY; Chu PH
    ESC Heart Fail; 2020 Oct; 7(5):2784-2796. PubMed ID: 32627380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.